Top Entrepreneurs’ Advice →
CEO and Fund Manager, Renaissance Venture Capital Fund
Managing director, the Foundry Group
Founder and CEO, Lighter Capital
VP of Research & Policy, Ewing Marion Kauffman Foundation
CEO of Dynamis Corporation
Founder and CEO of Brooks Bell Inc.
Managing Partner at Pappas Ventures
Founding Director, Massachusetts Technology Transfer Center
December 2, 2015 ·
December 10, 2015 ·
December 5th, 2007
GlaxoSmithKline has written Lexington, MA-based Synta Pharmaceuticals (NASDAQ: SNTA) a check for $80 million. The payment is the first installment under a cancer-drug development agreement that could ultimately be worth $1.1 billion for the Lexington firm.
Xconomy offers a number of ways to subscribe for free!
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit/Ann Arbor, San Francisco, New York, Raleigh-Durham, Boulder/Denver, Texas, Wisconsin and beyond.
© 2007-2015, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.
Website development support from Andrew Koyfman with design support from Rob Hunter.